ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2024
Blood tests for Alzheimer's disease: The impact of disease prevalence on test performance.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Electronic Health Records to Test Multimorbidity Influences to Plasma Biomarker Interpretation for Alzheimer's Disease.Annals of neurology · 2026Article
- Plasma brain-derived p-tau217 for the identification of amyloid status in a memory clinic cohort.Journal of neurology · 2026Article
- Article
- Comparison of plasma p-tau217/Aβ42, p-tau217, and Aβ42/Aβ40 biomarkers by race to detect Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Transitioning Alzheimer Disease Blood Biomarkers into Primary Care: Are We There Yet?Clinical chemistry · 2025Article
- Use of lecanemab and donanemab in the Canadian healthcare system: Evidence, challenges, and areas for future research.The journal of prevention of Alzheimer's disease · 2025Review
- A colorimetric nano-enzyme assay with Ni@Pt nanoparticles as signal labels for rapid and sensitive detection of exosomal Aβ42 in plasma.Mikrochimica acta · 2025Article
- Clinical validation of a plasma-based antibody-free LC-MS method for identifying CSF amyloid positivity in mild cognitive impairment.Frontiers in aging neuroscience · 2025Article
- ADNI Biomarker Core: A review of progress since 2004 and future challenges.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Plasma Neurodegenerative Biomarkers in Cognitively Preserved Nonagenarians.Aging and disease · 2024Article
- Performance of plasma p-tau217 for the detection of amyloid-β positivity in a memory clinic cohort using an electrochemiluminescence immunoassay.Alzheimer's research & therapy · 2024Article
- Clinical performance of the fully automated Lumipulse plasma p-tau217 assay in mild cognitive impairment and mild dementia.Alzheimer's & dementia (Amsterdam, Netherlands)Article
- Application of the revised criteria for diagnosis and staging of Alzheimer's disease: Drug development and clinical practice.Alzheimer's & dementia (New York, N. Y.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.